EsoCap AG is developing a unique targeted delivery platform technology for the treatment of patients with diseases of the esophagus.

EsoCap recently successfully completed the double-blind, randomised, placebo-controlled Phase II ACESO study in the lead indication eosinophilic esophagitis (EoE).

Location
Canton
Facts & figures
  • Type of organization
    Private company
  • Year of foundation
    2017
  • Number of employees in Switzerland
    1-9
Key business

You may also be interested in